Novo Holdings to buy contract manufacturer Catalent for $16.5 billion
By 
Anthony King2024-02-13T13:42:00
Parent firm will then sell on three manufacturing sites to Novo Nordisk to boost capacity for diabetes and weight loss drugs
Novo Holdings – the parent of Novo Nordisk and Novozymes – has agreed to buy contract drug manufacturing organisation (CDMO) Catalent for $16.5 billion (£13 billion). Novo Holdings will then transfer three of Catalent’s manufacturing sites to Novo Nordisk for $11 billion, to support Novo Nordisk’s efforts to meet surging demand for its injectable semaglutide-based diabetes and obesity drugs Ozempic and Wegovy.